Publications

Add filters (0)

263 results

How are patient-reported pain outcomes associated with biomarker and structural pathology subtypes in knee osteoarthritis? An explorative evaluation in the IMI-APPROACH cohort.

March 1, 2026

Osteoarthr Cartil Open

Abstract OBJECTIVE To explore associations between patient-reported pain outcomes and knee osteoarthritis (OA) subtypes based on systemic biochemical markers and joint structural pathology as defined by MRI. METHODS Data were obtained from 297 knee OA patients from the IMI-APPROACH study. Pain outcomes were assessed using the KOOS, WOMAC, ICOAP, NRS, PainDETECT, and a pain diary. […]

Read publication

The role of type I collagen fragment C1M in knee osteoarthritis. A longitudinal biomarker study using data from the OA-FNIH consortium.

February 24, 2026

Osteoarthritis Cartilage

Abstract OBJECTIVE To evaluate the association of neoepitopes from type I and II collagen with knee osteoarthritis (OA) progression phenotypes using data from the OA-FNIH biomarker consortium, with comparison to associations of the other biomarkers assessed in this sample during the consortium’s phase 1 analysis. DESIGN Serum (s) and urinary (u) neoepitopes of type I […]

Read publication

Cytokine profiling of molecular endotypes of knee osteoarthritis: insights from the IMI-APPROACH cohort.

January 27, 2026

Arthritis Res Ther

Abstract BACKGROUND Molecular endotypes that decipher the heterogeneity of osteoarthritis (OA) have been described. This exploratory study aimed to further the molecular understanding of three previously identified biomarker-based endotypes of knee OA through cytokine profiling. METHODS Fifteen pro- and anti-inflammatory cytokines were measured in serum at the six-, 12-, and 24-month follow-up visits of 277 […]

Read publication

Biochemical biomarkers of knee osteoarthritis progression: Results from the FNIH biomarkers consortium progress OA study.

December 1, 2025

Osteoarthr Cartil Open

Abstract OBJECTIVE The Foundation for National Institutes of Health (FNIH) OA Biomarkers Consortium aims to identify and qualify biomarkers to support drug development in knee osteoarthritis (OA). The PROGRESS OA study aims to externally validate prognostic biomarkers identified in the earlier Phase I study. DESIGN PROGRESS OA included data from the control arms of several […]

Read publication

Axial spondyloarthritis, psoriatic arthritis and systemic lupus erythematosus share common molecular features based on post-hoc analysis of serum biomarkers.

October 30, 2025

Rheumatol Int

Abstract UNLABELLED Axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE) are distinct rheumatological diseases with common molecular features. This study explored tissue-associated remodelling endotypes using blood-based biomarkers reflecting interstitial matrix and basement membrane remodelling. Baseline serum samples from radiographic axSpA (r-axSpA) (NCT02437162/NCT02438787) (= 66), PsA (NCT03158285) (= 267) and SLE (NCT02349061) (= 97) […]

Read publication

Diagnosing, treating and monitoring the inflammatory endotype in osteoarthritis clinical trials.

October 1, 2025

Expert Rev Mol Diagn

Abstract INTRODUCTION Osteoarthritis (OA) involves an inflammatory component, presenting as synovitis and systemic low-grade inflammation. Preliminary evidence suggests that anti-inflammatory treatments may offer symptomatic and structural benefits in OA. More targeted approaches have been proposed and tested, but the means of identifying the clinical and molecular characteristics of patients with an inflammatory subtype remains unclear. […]

Read publication

Serological assessment of PRO-C16 (type XVI collagen formation) reflects intestinal fibrostenotic strictures in patients with crohn’s disease.

August 8, 2025

BMC Gastroenterol

Abstract BACKGROUND Fibrostenotic stricturing disease affects 30-50% of patients with Crohn’s disease (CD), leading to intestinal resection. Currently, there exists a great medical need to identify biomarkers related to fibrostenotic strictures for optimized patient management. Thus, we investigated PRO-C16 as a biomarker for intestinal fibrosis in patients with CD. METHODS Human serum from two independent […]

Read publication

Fibroblast activities are associated with prolonged QTc and pulmonary arterial hypertension in patients with systemic sclerosis.

August 1, 2025

Clin Exp Rheumatol

Abstract OBJECTIVES In systemic sclerosis patients (SSc), we aimed at exploring the potential of serum biomarkers of fibrosis and immune-cell activity to detect subclinical heart involvement determined by electrocardiographic (ECG) alterations. METHODS A panel of extracellular matrix (ECM) turnover biomarkers quantifying type III and VI collagen formation (PRO-C3 and PRO-C6), type IV collagen turnover (PRO-C4), […]

Read publication

Serum biochemical marker of synovial tissue turnover, C1M, predicts radiological progression in early rheumatoid arthritis.

July 10, 2025

RMD Open

Abstract OBJECTIVES To investigate whether serum C1M and C2M, biochemical markers of synovial and cartilage tissue destruction, were associated with progression of joint damage in patients with early arthritis. METHODS 813 early arthritis patients (<6 months of symptoms, 82% with rheumatoid arthritis, 18% undifferentiated arthritis) from the prospective ESPOIR study were followed for 5 years. […]

Read publication

Neutrophil-mediated degradation of type III collagen is elevated in inflammatory bowel disease and DSS-induced colitis reflecting early mucosal damage.

July 1, 2025

Sci Rep

Abstract Inflammatory Bowel Disease (IBD) is characterized by mucosal injury in the gastrointestinal (GI) tract. During an abnormal immune response in the GI tract, excessive secretion of immune-cell proteases occurs. Neutrophils are the first responders, infiltrating into the inflamed interstitial matrix, where type III collagen accumulates. We aimed to develop a biomarker that reflects early […]

Read publication